Genetic variations in individuals may cause differences in the response to cholinesterase
inhibitor drugs used in the treatment of Alzheimer's disease (AD). Through this review, we …

Less than 6% of rare illnesses have an appropriate treatment option. Repurposed
medications for new indications are a cost-effective and time-saving strategy that results in …

Novel drug development is onerous, time consuming and overpriced process with
particularly low success and relatively high enfeebling rates. To overcome this burden, drug …

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most
common type of dementia. With no disease-curing drugs available and an ever-growing AD …

Alzheimer's disease (AD) is the most prevalent form of dementia, and age is strongly
associated with the incidence of AD. This study aimed to investigate the association …

The clinical response to donepezil in patients with mild and moderate dementia was
investigated in relation to the drug plasma concentration and APOE and CYP2D6 …

Background The efficacy of acetylcholinesterase inhibitors (AChE-I) might depend on blood
concentration. While rivastigmine metabolism is independent of the cytochrome P450 …

Background Acetylcholinesterase inhibitors (AChE-I) are recommended for the treatment of
cognitive symptoms but also of behavioral and psychological symptoms in dementia. They …

Purpose Donepezil, a drug frequently used to treat dementia, is mainly metabolized by
cytochrome P450 2D6 (CYP2D6). This study investigated the relationships between …

Donepezil (DPZ) is an acetylcholine-esterase inhibitor currently used as the frontline drug to
treat Alzheimer's disease. The aim of this study was to investigate the possibility of …